German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GVHD): Guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD

British Journal of Dermatology

Volumn 165, Issue 1, 2011, Pages 18-29

  Marks, C ^a   Stadler, M ^b   Hausermann P ^c   Wolff, D ^d   Buchholz, S ^b   Stary, G ^e   Lee, S ^f   Lawitschka, A ^g   Bertz, H ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e Universitatsklinik fur Dermatologie   (Austria)

^f USA   (United States)

^g ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BLACK TEA EXTRACT; BOSENTAN; CLOBETASOL PROPIONATE; CLOFAZIMINE; COTRIMOXAZOLE; DESLORATADINE; DEXPANTHENOL; EMOLLIENT AGENT; GABAPENTIN; GLYCEROL; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; HYDROQUINONE; HYDROXYZINE; IMATINIB; METHOTREXATE; MOMETASONE FUROATE; PIMECROLIMUS; POLIDOCANOL; PSORALEN; QUINOLONE DERIVATIVE; RETINOIC ACID; RITUXIMAB; SILDENAFIL; SUNSCREEN; TACROLIMUS; TRIAMCINOLONE ACETONIDE; VORICONAZOLE;

ALOPECIA; AUSTRIA; BURNING SENSATION; CANCER EPIDEMIOLOGY; CHRONIC GRAFT VERSUS HOST DISEASE; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; DRUG CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FASCIITIS; GERMANY; HUMAN; HYPERPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; LUBRICATION; NAIL DYSTROPHY; NONHUMAN; PHOTOSENSITIVITY; PHOTOTHERAPY; PHOTOTOXICITY; PHYSIOTHERAPY; POLYMYOSITIS; PRIORITY JOURNAL; PRURITUS; PUVA; QUALITY OF LIFE; REVIEW; SKIN ATROPHY; SKIN CANCER; SKIN DISEASE; SKIN INFECTION; SKIN PROTECTION; SKIN ULCER; SWITZERLAND; TOPICAL TREATMENT; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; WOUND CARE;

AUSTRIA; CHRONIC DISEASE; EMOLLIENTS; GERMANY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUSCULOSKELETAL DISEASES; SKIN DISEASES; SWITZERLAND; ULTRAVIOLET THERAPY;

EID: 79959702660     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10360.x     Document Type: Review

References (84)

1. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-56. (Pubitemid 41754712)
2. Goerner M, Gooley T, Flowers ME, et al. Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. Biol Blood Marrow Transplant 2002; 8: 47-56. (Pubitemid 34141551)
3. Wingard JR, Vogelsang GB, Deeg HJ,. Stem cell transplantation: supportive care and long-term complications. Hematology Am Soc Hematol Educ Program 2002; 1: 422-44.
4. Lee SJ, Kim HT, Ho VT, et al. Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant 2006; 38: 305-10. (Pubitemid 44203780)
5. Couriel DR,. Ancillary and supportive care in chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 291-307. (Pubitemid 351720435)
6. Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft-versus-host disease in the clinical practice. Biol Blood Marrow Transplant 2010; 17: 167-75.
7. Kitajima T, Imamura S,. Graft-versus-host reaction enhanced by ultraviolet radiation. Arch Dermatol Res 1993; 285: 499-501. (Pubitemid 23310080)
8. Murphy GM,. Ultraviolet radiation and immunosuppression. Br J Dermatol 2009; 161 (Suppl. 3): 90-5.
9. Cowen EW, Hymes SR,. Cutaneous manifestations of chronic graft versus host disease. In: Chronic Graft Versus Host Disease, Interdisciplinary Management (, Vogelsang GB, Pavletic SZ, eds). New York: Cambridge University Press, 2009; 169-81.
10. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med 1997; 336: 897-904. (Pubitemid 27137189)
11. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. Ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2006; 12: 375-96. (Pubitemid 43380955)
12. Li L, Chan L, Gerber LH,. Rehabilitation evaluation and treatment of patients with chronic graft versus host disease. In: Chronic Graft Versus Host Disease, Interdisciplinary Management (, Vogelsang GB, Pavletic SZ, eds). New York: Cambridge University Press, 2009; 252-67.
13. DeLord C, Treleaven J, Shepherd J, et al. Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia. Bone Marrow Transplant 1999; 23: 523-5. (Pubitemid 29117047)
14. Stratton P, Turner ML, Childs R, et al. Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. Obstet Gynecol 2007; 110: 1041-9. (Pubitemid 350059409)
15. Au WY, Yeung CK, Cheung MC, et al. Penile lichen sclerosus after allogeneic stem cell transplantation. Br J Dermatol 2008; 159: 470-2.
16. Nylander E, Wahlin YB, Lundskog B, et al. Genital graft-versus-host disease in a male following allogeneic stem cell transplantation. Acta Derm Venereol 2007; 87: 367-8.
17. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16: 1611-28.
18. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406-14. (Pubitemid 34761100)
19. Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood 2009; 113: 5074-82.
20. Conrotto D, Carrozzo M, Ubertalli AV, et al. Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. Transplantation 2006; 82: 1113-15. (Pubitemid 44632132)
21. Neuman DL, Farrar JE, Moresi JM, et al. Toxic absorption of tacrolimus [corrected] in a patient with severe acute graft-versus-host disease. Bone Marrow Transplant 2005; 36: 919-20. (Pubitemid 41655621)
22. Prot-Labarthe S, Therrien R, Champagne MA, et al. Toxic serum levels of tacrolimus after topical administration in an infant with severe cutaneous graft-versus-host disease. Bone Marrow Transplant 2007; 40: 295-6. (Pubitemid 47108478)
23. Choi CJ, Nghiem P,. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: a case series of 18 patients. Arch Dermatol 2001; 137: 1202-6. (Pubitemid 32847843)
24. Elad S, Or R, Resnick I, Shapira MY,. Topical tacrolimus-a novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int 2003; 16: 665-70. (Pubitemid 37193295)
25. Ziemer M, Gruhn B, Thiele JJ, et al. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J Am Acad Dermatol 2004; 50: 946-8. (Pubitemid 38685779)
26. Schmook T, Kraft J, Benninghoff B, et al. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant 2005; 36: 87-8. (Pubitemid 40946057)
27. Wollina U,. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007; 8: 157-73. (Pubitemid 46998543)
28. Deshyes P,. Cosmetic camouflage for a better quality of life. Ann Dermatol Venereol 2008; 135 (Suppl. 3): 208-10.
29. Knobler HY, Sagher U, Peled IJ, et al. Tolerance to donor-type skin in the recipient of a bone marrow allograft. Treatment of skin ulcers in chronic graft-versus-host disease with skin grafts from the bone marrow donor. Transplantation 1985; 40: 223-5. (Pubitemid 15007335)
30. Schulz S, Metz M, Siepmann D, et al. [Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series]. Hautarzt 2009; 60: 564-8.
31. Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on clinical practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2010; 17: 1-17.
32. Magro L, Mohty M, Catteau B, et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114: 719-22.
33. Olivieri A, Locatelli F, Zecca M, et al. Imatinib for refractory chronic graft-versus-host disease with fibrotic features. Blood 2009; 114: 709-18.
34. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756-62. (Pubitemid 44061381)
35. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 2007; 40: 273-7. (Pubitemid 47108472)
36. Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112: 1515-21.
37. Ambach A, Seo W, Bonnekoh B, et al. Low-dose combination therapy of severe digital ulcers in diffuse progressive systemic sclerosis with the endothelin-1 receptor antagonist bosentan and the phosphodiesterase V inhibitor sildenafil. J Dtsch Dermatol Ges 2009; 7: 888-91.
38. Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38: 265-73. (Pubitemid 44203776)
39. Stern RS,. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol 2001; 44: 755-61. (Pubitemid 32391161)
40. Stern RS, Liebman EJ, Vakeva L,. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study. J Natl Cancer Inst 1998; 90: 1278-84. (Pubitemid 28433472)
41. Stern RS, Lunder EJ,. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta-analysis. Arch Dermatol 1998; 134: 1582-5. (Pubitemid 29009260)
42. Altman JS, Adler SS,. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease. J Am Acad Dermatol 1994; 31: 505-7. (Pubitemid 24273330)
43. Enk CD, Elad S, Vexler A, et al. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant 1998; 22: 1179-83. (Pubitemid 29021127)
44. Brazzelli V, Grasso V, Muzio F, et al. Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. Br J Dermatol 2010; 162: 404-9.
45. Stern RS, Laird N,. The carcinogenic risk of treatments for severe psoriasis. Photochemotherapy follow-up study. Cancer 1994; 73: 2759-64. (Pubitemid 24166263)
46. Atkinson K, Weller P, Ryman W, et al. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1986; 1: 227-36.
47. Eppinger T, Ehninger G, Steinert M, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplantation 1990; 50: 807-11.
48. Ghoreschi K, Thomas P, Penovici M, et al. PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. Eur J Dermatol 2008; 18: 667-70.
49. Jampel RM, Farmer ER, Vogelsang GB, et al. PUVA therapy for chronic cutaneous graft-vs-host disease. Arch Dermatol 1991; 127: 1673-8.
50. Leiter U, Kaskel P, Krahn G, et al. Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. Photodermatol Photoimmunol Photomed 2002; 18: 183-90.
51. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transplant 1996; 17: 1061-7. (Pubitemid 26235855)
52. Calzavara Pinton P, Porta F, Izzi T, et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica 2003; 88: 1169-75. (Pubitemid 37362550)
53. Wetzig T, Sticherling M, Simon JC, et al. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005; 35: 515-19. (Pubitemid 40403356)
54. Grundmann-Kollmann M, Behrens S, Gruss C, et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol 2000; 42: 134-6. (Pubitemid 30470334)
55. Ziemer M, Thiele JJ, Gruhn B, et al. Chronic cutaneous graft-versus-host disease in two children responds to UVA1 therapy: improvement of skin lesions, joint mobility, and quality of life. J Am Acad Dermatol 2004; 51: 318-19.
56. Pavletic SZ, Martin P, Lee SJ, et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. Response criteria working group report. Biol Blood Marrow Transplant 2006; 12: 252-66. (Pubitemid 43273710)
57. Oda K, Nakaseko C, Ozawa S, et al. Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT. Bone Marrow Transplant 2009; 43: 159-67.
58. Stadler M, Achenbach A, Funke J, et al. Extracorporeal photopheresis for treatment of fasciitis in chronic graft-versus-host disease. Haematologica 2006; 91 (Suppl. 1): 113.
59. Janin A, Socie G, Devergie A, et al. Fasciitis in chronic graft-versus-host disease. A clinicopathologic study of 14 cases. Ann Intern Med 1994; 120: 993-8. (Pubitemid 24169278)
60. Baumann F, Bruhlmann P, Andreisek G, et al. MRI for diagnosis and monitoring of patients with eosinophilic fasciitis. AJR Am J Roentgenol 2005; 184: 169-74. (Pubitemid 40040923)
61. Horger M, Boss A, Bethge W, et al. MR findings in patients with disabling musculocutaneous chronic graft-versus-host disease. Skeletal Radiol 2008; 37: 885-94.
62. Jacobsohn DA, Rademaker A, Kaup M, et al. Skin response using NIH consensus criteria vs Hopkins scale in a phase II study for steroid-refractory chronic GVHD. Bone Marrow Transplant 2009; 44: 813-19.
63. Beredjiklian PK, Drummond DS, Dormans JP, et al. Orthopaedic manifestations of chronic graft-versus-host disease. J Pediatr Orthop 1998; 18: 572-5. (Pubitemid 28446802)
64. Carenzio G, Gherardi P, Bardoni MT, et al. Rehabilitation of chronic graft versus host disease in children. A clinical series. Eura Medicophys 2007; 43: 445-50.
65. Buckley SL, Skinner S, James P, et al. Focal scleroderma in children: an orthopaedic perspective. J Pediatr Orthop 1993; 13: 784-90. (Pubitemid 23304746)
66. Kim JB, Liakopoulou E, Watson JS,. Successful treatment of refractory joint contractures caused by sclerodermatous graft versus host disease. J Plast Reconstr Aesthet Surg 2008; 61: 1235-8.
67. Lee SJ, Wegner SA, McGarigle CJ, et al. Treatment of chronic graft-versus-host disease with clofazimine. Blood 1997; 89: 2298-302. (Pubitemid 27143275)
68. Giaccone L, Martin P, Carpenter P, et al. Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 2005; 36: 337-41. (Pubitemid 41195167)
69. Robin M, Guardiola P, Girinsky T, et al. Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. Transplantation 2005; 80: 634-42. (Pubitemid 41377751)
70. Dann EJ, Badian A, Stravets T, et al. Extracorporeal photochemotherapy for acute and chronic GvHD, a report of 102 patients treated in a single institution. Haematologica 2009; 94 (Suppl. 2): 225.
71. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant 2005; 35: 1187-93. (Pubitemid 40895175)
72. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Br J Haematol 2003; 122: 118-27. (Pubitemid 36819346)
73. Romano C, Rubegni P, De Aloe G, et al. Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol 2003; 17: 10-13. (Pubitemid 36167779)
74. Sbano P, Rubegni P, De Aloe GB, et al. Extracorporeal photochemotherapy for treatment of fasciitis in chronic graft-versus-host disease. Bone Marrow Transplant 2004; 33: 869-70. (Pubitemid 38519252)
75. George B, Danda D, Chandy M, et al. Polymyositis-an unusual manifestation of chronic graft-versus-host disease. Rheumatol Int 2001; 20: 169-70. (Pubitemid 32449117)
76. Parker P, Chao NJ, Ben-Ezra J, et al. Polymyositis as a manifestation of chronic graft-versus-host disease. Medicine (Baltimore) 1996; 75: 279-85. (Pubitemid 26337847)
77. Grauer O, Wolff D, Bertz H, et al. Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on clinical practice in chronic graft-versus-host disease. Brain 2010; 133: 2852-65.
78. Norkin M, Ratanatharathorn V, Ayash L, et al. Large pericardial effusion as a complication in adults undergoing SCT. Bone Marrow Transplant 2010; doi:. PMID: 21113188
79. Seber A, Khan SP, Kersey JH,. Unexplained effusions: association with allogeneic bone marrow transplantation and acute or chronic graft-versus-host disease. Bone Marrow Transplant 1996; 17: 207-11. (Pubitemid 26057309)
80. Lev A, Amariglio N, Spirer Z, et al. Specific self-antigen-driven immune response in pericardial effusion as an isolated GVHD manifestation. Bone Marrow Transplant 2010; 45: 1084-7.
81. Saito Y, Matsushima T, Doki N, et al. Pericardial graft vs. host disease in a patient with myelodysplastic syndrome following peripheral blood stem cell transplantation. Eur J Haematol 2005; 75: 65-7. (Pubitemid 40873964)
82. Ueda T, Manabe A, Kikuchi A, et al. Massive pericardial and pleural effusion with anasarca following allogeneic bone marrow transplantation. Int J Hematol 2000; 71: 394-7.
83. Law L, Tuscano J, Wun T, et al. Filgrastim treatment of acute myelogenous leukemia (M7) relapse after allogeneic peripheral stem cell transplantation resulting in both graft-versus-leukemia effect with cytogenetic remission and chronic graft-versus-host disease manifesting as polyserositis and subsequent bronchiolitis obliterans with organizing pneumonia. Int J Hematol 2002; 76: 360-4. (Pubitemid 43014101)
84. Toren A, Nagler A,. Massive pericardial effusion complicating the course of chronic graft-versus-host disease (cGVHD) in a child with acute lymphoblastic leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1997; 20: 805-7. (Pubitemid 27489192)